Description: BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Home Page: www.biosyent.com
RX Technical Analysis
2476 Argentia Road
Mississauga,
ON
L5N 6M1
Canada
Phone:
905 206 0013
Officers
| Name | Title |
|---|---|
| Mr. René C. Goehrum | Chairman, CEO & Pres |
| Mr. Robert J. March | VP of Fin. & CFO |
| Mr. Joost van der Mark | VP of Corp. Devel. |
| Ms. Neelu Atwal | Director of HR |
| Mr. Alfred D'Souza | Advisor |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 13.7552 |
|---|---|
| Trailing PE: | 15 |
| Price-to-Book MRQ: | 2.6733 |
| Price-to-Sales TTM: | 3.1029 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |